PURPOSE: There is substantial interpatient variability in etoposide pharmacokinetics. Pharmacokinetic adjustment to specific plasma concentrations may make it possible to define a therapeutic plasma concentration and relate drug target expression in the tumor to response. This study evaluated the combination of cisplatin with a prolonged infusion of etoposide phosphate (EP) in advanced breast cancer and correlated response to topoisomerase II expression. EXPERIMENTAL DESIGN: Eligible patients, previously treated with an anthracycline, received 60 mg/m(2) cisplatin, followed by a 5-day infusion of EP. Plasma etoposide levels were measured on days 2 and 4 of each cycle with adjustment of the infusion rate to achieve an initial target etoposide concentration of 2 micro g/ml or 1.5 micro g/ml. Primary tumor blocks were stained by immunohistochemistry for topoisomerase IIalpha and beta. RESULTS: Thirty-six patients, treated in three consecutive cohorts, received 145 cycles of chemotherapy. Targeting plasma etoposide concentration reduced interpatient pharmacokinetic variability (32% and 62% of patients, respectively, within 10% of target concentration on days 2 and 4; cycle 1). Significant hematological toxicity (89% of patients with at least one episode of grade III/IV neutropenia, 64% of patients with at least one episode of grade III/IV thrombocytopenia) was observed. Thirty-nine percent of patients achieved a partial response, and 19% had stable disease for at least 3 months. The median time to tumor progression was 4 months, with a median survival of 11 months. Topoisomerase IIalpha expression was significantly higher (P < 0.001) in responding patients compared with those with stable or progressive disease. There was no difference in topoisomerase IIbeta expression between groups. CONCLUSION: Cisplatin and infusional EP is an active, but intensive, schedule in heavily pretreated patients with breast cancer. Clinical response correlates with tumor topoisomerase IIalpha expression.
PURPOSE: There is substantial interpatient variability in etoposide pharmacokinetics. Pharmacokinetic adjustment to specific plasma concentrations may make it possible to define a therapeutic plasma concentration and relate drug target expression in the tumor to response. This study evaluated the combination of cisplatin with a prolonged infusion of etoposide phosphate (EP) in advanced breast cancer and correlated response to topoisomerase II expression. EXPERIMENTAL DESIGN: Eligible patients, previously treated with an anthracycline, received 60 mg/m(2) cisplatin, followed by a 5-day infusion of EP. Plasma etoposide levels were measured on days 2 and 4 of each cycle with adjustment of the infusion rate to achieve an initial target etoposide concentration of 2 micro g/ml or 1.5 micro g/ml. Primary tumor blocks were stained by immunohistochemistry for topoisomerase IIalpha and beta. RESULTS: Thirty-six patients, treated in three consecutive cohorts, received 145 cycles of chemotherapy. Targeting plasma etoposide concentration reduced interpatient pharmacokinetic variability (32% and 62% of patients, respectively, within 10% of target concentration on days 2 and 4; cycle 1). Significant hematological toxicity (89% of patients with at least one episode of grade III/IV neutropenia, 64% of patients with at least one episode of grade III/IV thrombocytopenia) was observed. Thirty-nine percent of patients achieved a partial response, and 19% had stable disease for at least 3 months. The median time to tumor progression was 4 months, with a median survival of 11 months. Topoisomerase IIalpha expression was significantly higher (P < 0.001) in responding patients compared with those with stable or progressive disease. There was no difference in topoisomerase IIbeta expression between groups. CONCLUSION:Cisplatin and infusional EP is an active, but intensive, schedule in heavily pretreated patients with breast cancer. Clinical response correlates with tumor topoisomerase IIalpha expression.
Authors: Yaning Zhao; N A Yuan; Kuanzhi Li; Y I Geng; Haiping Zhou; Hua Wang; Jie Hou; Bin Zhang; Yuan Cai; Xinhan Zhao Journal: Oncol Lett Date: 2015-04-14 Impact factor: 2.967
Authors: Ki-Up Kim; Shannon M Wilson; Keith S Abayasiriwardana; Rodney Collins; Lars Fjellbirkeland; Zhidong Xu; David M Jablons; Stephen L Nishimura; V Courtney Broaddus Journal: Am J Respir Cell Mol Biol Date: 2005-08-25 Impact factor: 6.914
Authors: Chunyu Zhang; Abdel G Elkahloun; Matthew Robertson; Joell J Gills; Junji Tsurutani; Joanna H Shih; Junya Fukuoka; M Christine Hollander; Curtis C Harris; William D Travis; Jin Jen; Phillip A Dennis Journal: PLoS One Date: 2011-08-24 Impact factor: 3.240
Authors: N C Levitt; D J Propper; S Madhusudan; J P Braybrooke; C Echeta; R Te Poele; S L Davies; E Flanagan; I D Hickson; S Joel; T S Ganesan Journal: Br J Cancer Date: 2005-07-11 Impact factor: 7.640
Authors: E Franceschi; G Cavallo; L Scopece; A Paioli; A Pession; E Magrini; R Conforti; E Palmerini; S Bartolini; S Rimondini; R Degli Esposti; L Crinò Journal: Br J Cancer Date: 2004-09-13 Impact factor: 7.640